Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RGEN 
Repligen Corporation (RGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $179.72
1 Year Target Price $179.72
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.55% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.88B USD | Price to earnings Ratio - | 1Y Target Price 179.72 |
Price to earnings Ratio - | 1Y Target Price 179.72 | ||
Volume (30-day avg) 19 | Beta 1.05 | 52 Weeks Range 102.97 - 182.52 | Updated Date 08/29/2025 |
52 Weeks Range 102.97 - 182.52 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.05% | Operating Margin (TTM) 5.28% |
Management Effectiveness
Return on Assets (TTM) 1.13% | Return on Equity (TTM) -0.68% |
Valuation
Trailing PE - | Forward PE 73.53 | Enterprise Value 6850202191 | Price to Sales(TTM) 10.21 |
Enterprise Value 6850202191 | Price to Sales(TTM) 10.21 | ||
Enterprise Value to Revenue 10.16 | Enterprise Value to EBITDA 68.84 | Shares Outstanding 56257600 | Shares Floating 52655443 |
Shares Outstanding 56257600 | Shares Floating 52655443 | ||
Percent Insiders 6.4 | Percent Institutions 104.79 |
Upturn AI SWOT
Repligen Corporation
Company Overview
History and Background
Repligen Corporation was founded in 1981. It initially focused on developing recombinant protein A and has since evolved into a leading provider of bioprocessing technologies and solutions. Key milestones include strategic acquisitions and product innovations in chromatography, filtration, and process analytics.
Core Business Areas
- Filtration: Provides filtration products and systems used in biomanufacturing processes for purification and concentration of biological products.
- Chromatography: Offers chromatography products, including resins and systems, used for separating and purifying biomolecules.
- Process Analytics: Develops and supplies process analytics tools and sensors that monitor and control critical parameters in bioprocessing.
- Cell Culture: Provides cell culture products used in bioprocessing for the development of cell lines and generation of biological products.
Leadership and Structure
Tony J. Hunt is the President and CEO. The company has a typical corporate structure with departments focused on R&D, manufacturing, sales, and marketing, reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- OPUS(R) Pre-packed Columns: Pre-packed chromatography columns used for purification of proteins and other biomolecules. Repligen has a significant market share in this segment. Competitors include Cytiva (formerly GE Healthcare Life Sciences) and Bio-Rad Laboratories. Revenue from OPUS is a significant contributor to overall sales.
- KrosFlo(R) Filtration Systems: Tangential flow filtration (TFF) systems used for separation and purification of biomolecules. Repligen is a key player. Competitors include Sartorius Stedim Biotech and Danaher Corporation (Pall Life Sciences). Revenue from KrosFlo systems is significant in overall sales.
- NovaSeptum(R) Sampling Systems: Sterile sampling systems used in bioprocessing for monitoring and control. Repligen has a growing market presence. Competitors include Sartorius Stedim Biotech. Revenue for NovaSeptum contributes to process analytics sales.
Market Dynamics
Industry Overview
The bioprocessing industry is experiencing strong growth driven by increasing demand for biologics, biosimilars, and cell and gene therapies. Technological advancements and regulatory requirements are key drivers.
Positioning
Repligen is positioned as a leading provider of bioprocessing solutions, with a focus on innovation, quality, and customer service. Its competitive advantages include a broad product portfolio, strong technical expertise, and established relationships with key customers.
Total Addressable Market (TAM)
The TAM for bioprocessing technologies is estimated to be billions of dollars annually. Repligen is well-positioned to capture a significant share of this market due to its strong product portfolio and market presence.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Leading market position in key segments
- Innovative technology
- Established customer relationships
- Experienced management team
Weaknesses
- Dependence on the biopharmaceutical industry
- Competition from larger players
- Potential for product recalls
- Integration risks associated with acquisitions
Opportunities
- Expanding into new geographic markets
- Developing new products and technologies
- Acquiring complementary businesses
- Capitalizing on the growth of cell and gene therapy
Threats
- Economic downturn
- Changes in regulations
- Increased competition
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Cytiva
- Sartorius Stedim Biotech
- Danaher (Pall Life Sciences)
- Thermo Fisher Scientific
Competitive Landscape
Repligen has a strong competitive position due to its specialized product portfolio and focus on bioprocessing. However, it faces competition from larger, more diversified companies.
Major Acquisitions
Phenomenex
- Year: 2023
- Acquisition Price (USD millions): 775
- Strategic Rationale: Expanded Repligen's chromatography portfolio and strengthened its presence in the bioprocessing market.
Growth Trajectory and Initiatives
Historical Growth: Repligen has experienced significant revenue growth in recent years, driven by strong demand for its products and strategic acquisitions.
Future Projections: Future growth projections vary based on analyst estimates and market conditions.
Recent Initiatives: Recent initiatives include product launches, acquisitions of complementary businesses, and expansion into new geographic markets.
Summary
Repligen is a strong player in the bioprocessing market, driven by its innovative products and strategic acquisitions. The company's focus on cell and gene therapy presents a significant opportunity. Repligen needs to navigate competition from larger players and manage integration risks from acquisitions. Overall, Repligen shows great potential for continued growth. However, economic downturns could impact the company's growth prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available information. The AI-based rating is subjective and should be used as one factor in investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repligen Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Olivier Loeillot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1778 | Website https://www.repligen.com |
Full time employees 1778 | Website https://www.repligen.com | ||
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.